MedPath

Hanlim Pharm Co., Ltd.

Hanlim Pharm Co., Ltd. logo
🇰🇷South Korea
Ownership
Private
Established
1989-03-14
Employees
251
Market Cap
-
Website
http://hanlim.com

Study to Evaluate Efficacy and Safety of Entelon 50mg in Patients With Non-Proliferative Diabetic Retinopathy

Phase 4
Recruiting
Conditions
Non Proliferative Diabetic Retinopathy
Interventions
Drug: Placebo
Drug: Entelon Tab. 50mg
First Posted Date
2022-05-03
Last Posted Date
2022-07-21
Lead Sponsor
Hanlim Pharm. Co., Ltd.
Target Recruit Count
396
Registration Number
NCT05358080
Locations
🇰🇷

Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea, Republic of

Phase 4 Study to Evaluate Efficacy and Safety of Entelon Tab.150mg in Patients With Chronic Venous Disease(CVD)

Phase 4
Conditions
Chronic Venous Disease
Interventions
Drug: Venitol Tab.
Drug: Entelon Tab.150mg
Drug: Placebo of Venitol Tab.
Drug: Placebo of Entelon Tab.150mg
First Posted Date
2021-05-11
Last Posted Date
2021-05-11
Lead Sponsor
Hanlim Pharm. Co., Ltd.
Target Recruit Count
278
Registration Number
NCT04882228
Locations
🇰🇷

Bundang Seoul University Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of

Study to Evaluate the Safety and PK of LODIENT Tablet 80/2.5mg in Healthy Adult Volunteers

Phase 1
Completed
Conditions
Hypertension
Interventions
Drug: LodineT
First Posted Date
2020-12-16
Last Posted Date
2020-12-16
Lead Sponsor
Hanlim Pharm. Co., Ltd.
Target Recruit Count
32
Registration Number
NCT04667624
Locations
🇰🇷

Metro Hospital, Anyang, Kyung Gi, Korea, Republic of

To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia

Phase 3
Conditions
Primary Hypercholesterolemia
Hypertension
First Posted Date
2020-12-09
Last Posted Date
2020-12-09
Lead Sponsor
Hanlim Pharm. Co., Ltd.
Target Recruit Count
156
Registration Number
NCT04659070
Locations
🇰🇷

Daegu Catholic Univ Medical Center, Daegu, Korea, Republic of

Phase 2a Clinical Trial of HL237 for Rheumatoid Arthritis

Phase 2
Conditions
Rheumatoid Arthritis
Interventions
Drug: HL237 tablet
Drug: Placebo of HL237 tablet
First Posted Date
2020-11-20
Last Posted Date
2020-11-20
Lead Sponsor
Hanlim Pharm. Co., Ltd.
Target Recruit Count
196
Registration Number
NCT04638426
Locations
🇰🇷

The Catholic University of Korea Seoul ST.MARY'S Hospital, Seoul, Korea, Republic of

The Study of Pharmacokinetic Interactions Between HL237 and Tacrolimus

Phase 1
Conditions
Healthy Male Volunteers
Interventions
Drug: HL237 tablet
First Posted Date
2020-11-18
Last Posted Date
2020-11-18
Lead Sponsor
Hanlim Pharm. Co., Ltd.
Target Recruit Count
24
Registration Number
NCT04633733
Locations
🇰🇷

The Korea Univertisy Anam Hospital, Seoul, Korea, Republic of

Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of HL301 on Radiation Pneumonitis in Non-small Cell Lung Cancer Patients

Phase 2
Conditions
Lung Cancer
Radiation Pneumonitis
Interventions
Drug: HL301 tablet 300mg
Drug: Placebo of HL301 tablet
First Posted Date
2020-11-17
Last Posted Date
2020-11-17
Lead Sponsor
Hanlim Pharm. Co., Ltd.
Target Recruit Count
87
Registration Number
NCT04632342
Locations
🇰🇷

Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

To Evaluate the Efficacy and Safety of LuminoMark Injection in Patients With Nonpalpable Breast Lesions(Phase 3)

Phase 3
Completed
Conditions
Breast Diseases
Interventions
Drug: LuminoMark inj.(Conc. for fluorescence)
Drug: Charcotrace Inj.
First Posted Date
2020-10-28
Last Posted Date
2021-02-10
Lead Sponsor
Hanlim Pharm. Co., Ltd.
Target Recruit Count
109
Registration Number
NCT04606329
Locations
🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

Study to Evaluate HL-TOF Tab. 5 mg Compared With XelJanz Tab. in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: HL-TOF tab. 5mg
First Posted Date
2019-10-03
Last Posted Date
2020-05-12
Lead Sponsor
Hanlim Pharm. Co., Ltd.
Target Recruit Count
33
Registration Number
NCT04114461
Locations
🇰🇷

YANGJI Hospital, Seoul, Korea, Republic of

A Multiple Dose of HL237 in Healthy Male Subject

Phase 1
Conditions
Rheumatoid Arthritis
Interventions
Drug: Placebo Oral Tablet
First Posted Date
2019-04-01
Last Posted Date
2019-04-02
Lead Sponsor
Hanlim Pharm. Co., Ltd.
Target Recruit Count
36
Registration Number
NCT03896594
Locations
🇰🇷

The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul, Seocho-gu, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath